Healthcare Provider Awareness and Integration of Immunotherapy for Stage III NSCLC

This poster, presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, reports an analysis of healthcare provider uptake of immune checkpoint inhibitor therapy for the treatment of unresectable stage III NSCLC in the 9 months following its approval. Self-reported practice trends at baseline showed that most HCPs were not optimally treating unresectable stage III NSCLC prior to attending the symposia. However, post-education data suggest that HCPs are willing to modify their practice in this setting after receiving expert led education and guidance.


Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?